VBI Vaccines Inc.

VBI Vaccines — Corporate Update (July 2017)

11 slides from VBI Vaccines's corporate update, Jul 27, 2017

  1. Slide 1: VBI Vaccines CMV Update

    £3 VBI VACCINES cer UPDATE NASDAQ: VBIV TSX: VBV

  2. Slide 2: Cautionary Statement Regarding Forward-Looking Information

    Cautionary Statement Regarding Forward-Looking Information Certain statementsin this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 an

  3. Slide 3: Agenda

    ———————————— Agenda 1. INTRODUCTION 2. OVERVIEW OF CYTOMEGALOVIRUS (CMV) 3. PHASE I CLINICAL STUDY— DESIGN & INTERIM DATA READ-OUT 4, SUMMARY OF NEAR-TERM MILESTONES 5. Q&A NASDAQ: VBIV | TSK: VBV 3

  4. Slide 4: What is CMV?

    What is CMV? CYTOMEGALOVIRUS (CMV) IS A COMMON VIRUS THAT INFECTS ONE IN EVERY TWO PEOPLE IN MANY DEVELOPED COUNTRIES * Most CMVinfections are “silent” — most people who are infected with CMV exhibit no signs or symptoms * However, CMV can cause serious disease in newborns when a womanis infected du

  5. Slide 5: CMV Disease Burden

    | CMV Disease Burden = Each year, approximately 30,000 infants are born each year with CMV infection, of which more than 5,000 U.S. infants will develop permanent problems = Inthe U.S., the direct economic costs of CMV infection exceeds $3.0B annually U.S. CHILDREN BORN WITH OR DEVELOPING LONG-TERM

  6. Slide 6: CMV Phase I Clinical Trial Overview

    CMV Phase | Clinical Trial Overview Opportunity for Immunologic Human Proof of Concept with Ph | Data TRIAL DESIGN + Enrolled Population: 128 CMV-Negative Healthy Adults (18-40 yrs) + Design: Observer-blind five arm study, subjects randomized in a 1:1:1:1 ratio to receive vaccination at month 0, 2,

  7. Slide 7: Interim Phase I Immunogenicity Signals (1)

    Interim Phase | Immunogenicity Signals (1) BASED ON SUBJECT SAMPLES COLLECTED 1 MONTH AFTER 2™° VACCINATION After two vaccinations, immunization of subjects with the highest dose of VBI-1501A (2.0g) induced: Seroconversion* in 100% of subjects Adjuvant (alum) enhances immunogenicity Neutralizing ant

  8. Slide 8: Interim Phase I Immunogenicity Signals (2)

    Interim Phase | Immunogenicity Signals (2) BASED ON SUBJECT SAMPLES COLLECTED 1 MONTH AFTER 2N° VACCINATION Clear dose-dependent boosting of response: 25: Fold-increase is based on comparison of antibody binding GMTs at day 56 (post 1* vaccination) vs. day 84 (1 month post 2™ vaccination) Fold-incre

  9. Slide 9: Interim Phase I Data Summary

    Interim Phase | Data Summary * VBI-1501Ais safe and well tolerated at all doses tested * VBI-1501Ais immunogenic after 2 doses Evidence of strong boosting in antibody titers observed, which is dose-dependent © Observed neutralizing antibodies against epithelial cell infection in some subjects is enc

  10. Slide 10: Expected Near-Term Milestones by Program

    eT Expected Near-Term Milestones by Program TB VBI-1501A: Congenital CMV fj * H1 2018: Final Phase | clinical study results SCI-B-VAC™ : Hepatitis B fj * H2 2017: Initiation of enrollment in Phase III program * H1 2019: Phase Ill results expected TH B VBI-1901 : Glioblastoma Multiforme (GBM) §j * H2

  11. Slide 11: Zam

    wm, =v0l G Zam \\ “iif\i\\\\ VBI Vaccines Inc. 222 Third Street, Suite 2241 Cambridge, MA 02142 (617) 830-3031 info@vbivaccines.com

VBI Vaccines — Corporate Update (July 2017) on 6ix